Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9221007 | 0.81 | KMT2A (0.38) | CSNK2A2CSNK2BCSNK2A1KMT2AADORA2A | |
| SCHEMBL24511817 | 0.68 | CSNK2A2 (0.41) | CSNK2A2CSNK2BCSNK2A1KMT2A | |
| SCHEMBL15243045 | 0.62 | CSNK2A2 (0.35) | CSNK2A2CSNK2BCSNK2A1ADORA3ADORA2A | |
| SCHEMBL5929142 | 0.61 | CSNK2A2 (0.52) | CSNK2A2CSNK2BCSNK2A1ADORA3ADORA2A | |
| SCHEMBL11469986 | 0.61 | CYP3A4 (0.30) | CYP3A4 | |
| SCHEMBL15243046 | 0.61 | RAB9A (0.35) | CSNK2A2CSNK2BCSNK2A1CYP3A4 | |
| SCHEMBL11461855 | 0.60 | — | — | |
| SCHEMBL12332804 | 0.58 | KDM4E (0.31) | — | |
| SCHEMBL11784338 | 0.58 | RAB9A (0.33) | KMT2A | |
| SCHEMBL16557019 | 0.58 | KDM4E (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2026-02-05 | — | — | US | disclosed |
| US-12453734-B2 | Modulators of rho-associated protein kinase | REDX PHARMA LIMITED (GB) | 2025-10-28 | — | — | US | disclosed |
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| US-11878020-B2 | Modulators of Rho-associated protein kinase | REDX PHARMA PLC (GB) | 2024-01-23 | — | — | US | disclosed |
| CN-111655681-B | Heterocyclylamino-substituted triazoles as modulators of Rho-related protein kinases | 莱德克斯制药公共有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| US-11497751-B2 | Modulators of Rho-associated protein kinase | REDX PHARMA PLC (GB) | 2022-11-15 | — | — | US | disclosed |
| EP-4026834-A1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | Redx Pharma Plc (GB) | 2022-07-13 | — | — | EP | disclosed |
| EP-4026834-A1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | Redx Pharma Plc (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-8865910-B2 | 1, 2, 4-triazole derivatives and their anti mycobacterial activity | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-10-21 | — | — | US | disclosed |
| EP-2523949-B1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| WO-2014070978-A1 | INHIBITORS OF CYTOMEGALOVIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-08 | — | — | WO | disclosed |
| US-20130060045-A1 | 1, 2, 4-TRIAZOLE DERIVATIVES AND THEIR ANTI MYCOBACTERIAL ACTIVITY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-03-07 | — | — | US | disclosed |
| US-20130060045-A1 | 1, 2, 4-TRIAZOLE DERIVATIVES AND THEIR ANTI MYCOBACTERIAL ACTIVITY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-03-07 | — | — | US | disclosed |
| US-20130060045-A1 | 1, 2, 4-TRIAZOLE DERIVATIVES AND THEIR ANTI MYCOBACTERIAL ACTIVITY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-03-07 | — | — | US | disclosed |
| US-20120295891-A1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-11-22 | — | — | US | disclosed |
| US-20120295891-A1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-11-22 | — | — | US | disclosed |
| WO-2011111077-A1 | 1, 2, 4-TRIAZOLE DERIVATIVES AND THEIR ANTI MYCOBACTERIAL ACTIVITY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011086099-A1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034140-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | CSNK2A2 229/4885CSNK2B 309/4885CSNK2A1 271/4885 |
| US-12453734-B2 | Modulators of rho-associated protein kinase | ROCK2, ROCK1, RHOA | CSNK2A2 394/4885CSNK2B 558/4885CSNK2A1 422/4885 |
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | CSNK2A2 394/4885CSNK2B 558/4885CSNK2A1 422/4885 |
| US-20120295891-A1 | NOVEL SUBSTITUTED TRIAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APH1A | CSNK2A2 747/4885CSNK2B 704/4885CSNK2A1 533/4885 |
| US-11497751-B2 | Modulators of Rho-associated protein kinase | ROCK2, ROCK1, RHOA | CSNK2A2 401/4885CSNK2B 582/4885CSNK2A1 444/4885 |
| US-20130060045-A1 | 1, 2, 4-TRIAZOLE DERIVATIVES AND THEIR ANTI MYCOBACTERIAL ACTIVITY | NAT1, CBR3, NOX3 | CSNK2A2 3001/4885CSNK2B 2034/4885CSNK2A1 2185/4885 |
| US-11878020-B2 | Modulators of Rho-associated protein kinase | ROCK2, ROCK1, RHOA | CSNK2A2 394/4885CSNK2B 558/4885CSNK2A1 422/4885 |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | CSNK2A2 394/4885CSNK2B 558/4885CSNK2A1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.